MA29268B1 - Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse - Google Patents

Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse

Info

Publication number
MA29268B1
MA29268B1 MA30164A MA30164A MA29268B1 MA 29268 B1 MA29268 B1 MA 29268B1 MA 30164 A MA30164 A MA 30164A MA 30164 A MA30164 A MA 30164A MA 29268 B1 MA29268 B1 MA 29268B1
Authority
MA
Morocco
Prior art keywords
tablets
improved dispersibility
vehicle
medicinal substance
spray granulation
Prior art date
Application number
MA30164A
Other languages
English (en)
Inventor
Nathalie Bernigal
Eric Garcia
Susanne Page
Joseph Tardio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36406213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29268(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA29268B1 publication Critical patent/MA29268B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION SE RAPPORTE À UN PROCÉDÉ PERMETTANT DE PRÉPARER DES COMPOSITIONS PHARMACEUTIQUES SE PRÉSENTANT SOUS FORME DE COMPRIMÉS ET DOTÉES D'UNE DISPERSIBILITÉ DE SUBSTANCE MÉDICAMENTEUSE AMÉLIORÉE. LEDIT PROCÉDÉ EST CARACTÉRISÉ EN CE QU'IL COMPREND LES ÉTAPES SUIVANTES : (A) PRÉPARATION D'UNE DISPERSION D'AU MOINS UNE SUBSTANCE MÉDICAMENTEUSE PHARMACEUTIQUEMENT ACTIVE ET D'AU MOINS UN TENSIO-ACTIF ET/OU UN LIANT DANS UN LIQUIDE ; (B) PRÉPARATION D'UN VÉHICULE, PAR LE MÉLANGE SEC D'UN OU PLUSIEURS EXCIPIENTS, DONT AU MOINS UN VÉHICULE POREUX ; ET (C) GRANULATION PAR PULVÉRISATION DE LA DISPERSION PRÉPARÉE À L'ÉTAPE (A) SUR LE VÉHICULE PRÉPARÉ À L'ÉTAPE (B), AFIN D'OBTENIR UN PRODUIT DE GRANULATION PAR PULVÉRISATION.
MA30164A 2005-02-25 2007-08-24 Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse MA29268B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101458 2005-02-25

Publications (1)

Publication Number Publication Date
MA29268B1 true MA29268B1 (fr) 2008-02-01

Family

ID=36406213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30164A MA29268B1 (fr) 2005-02-25 2007-08-24 Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse

Country Status (20)

Country Link
US (2) US20060193910A1 (fr)
EP (2) EP2281556A1 (fr)
JP (1) JP2008531509A (fr)
KR (1) KR20070094666A (fr)
CN (1) CN101128189A (fr)
AR (1) AR055561A1 (fr)
AU (1) AU2006218193A1 (fr)
BR (1) BRPI0606187A2 (fr)
CA (1) CA2598762A1 (fr)
CR (1) CR9292A (fr)
IL (1) IL185011A0 (fr)
MA (1) MA29268B1 (fr)
MX (1) MX2007009571A (fr)
NO (1) NO20074092L (fr)
NZ (1) NZ560232A (fr)
RU (1) RU2007129642A (fr)
TW (1) TW200640502A (fr)
UA (1) UA90708C2 (fr)
WO (1) WO2006089674A2 (fr)
ZA (1) ZA200706495B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2007122635A2 (fr) * 2006-04-26 2007-11-01 Astron Research Limited Formulation à libération à libération contrôlée comprenant des médicaments anti-épilepiques
CA2702055C (fr) * 2007-10-10 2017-12-12 Mallinckrodt Baker, Inc. Excipient a base de cellulose microcristalline granulaire a fonctionnalite elevee directement compressible, son procede de fabrication et son utilisation
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
CN102292074B (zh) * 2009-01-23 2013-08-21 霍夫曼-拉罗奇有限公司 包含阿格列扎的药物组合物
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
HRP20140759T1 (hr) 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
CN102641302B (zh) * 2011-02-18 2016-01-20 上海张江中药现代制剂技术工程研究中心 一种提高中药提取物浸膏粉软化点的方法
RU2468789C1 (ru) * 2011-05-04 2012-12-10 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения атеросклероза
CN104784239B (zh) * 2015-04-28 2017-12-26 新乡医学院第一附属医院 一种快速溶出的珍菊降压片及其制备工艺
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
WO2017003137A1 (fr) * 2015-06-30 2017-01-05 (주)아모레퍼시픽 Composition nettoyante granulaire à désintégration rapide pour les cheveux
AU2017361254B2 (en) * 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
EP3541807B1 (fr) 2016-11-16 2021-09-29 H. Lundbeck A/S Une forme cristalline d'un inhibiteur de magl
CN109701441B (zh) * 2018-12-16 2021-04-09 桂林理工大学 一种卵磷脂选择性改性高岭石的制备方法及其应用
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN111548218A (zh) * 2020-04-27 2020-08-18 上海应用技术大学 一种通用型花肥速释片及其制备方法和应用
CN116602928A (zh) * 2023-06-30 2023-08-18 康普药业股份有限公司 一种甲苯磺酸艾多沙班组合物和制备方法
US12296050B2 (en) * 2023-10-05 2025-05-13 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof
CN119857081B (zh) * 2025-01-16 2025-10-17 江苏亚邦爱普森药业有限公司 一种乌帕替尼缓释片及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653203B2 (en) * 1991-01-30 1994-09-22 Wellcome Foundation Limited, The Water-dispersible tablets
ATE195867T1 (de) 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
JP4334616B2 (ja) * 1994-09-22 2009-09-30 ナームローゼ・フエンノートチヤツプ・オルガノン 湿式粒状化による投与単位体を製造する方法
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
WO1998024441A1 (fr) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des etats depressifs majeurs accompagnes d'anxiete
ATE285776T1 (de) 1996-12-02 2005-01-15 Merck Sharp & Dohme Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
GB9825242D0 (en) 1998-11-19 1999-01-13 Cambridge Advanced Tech Genetically modified plants with altered starch
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
CN1134417C (zh) 1999-02-24 2004-01-14 弗·哈夫曼-拉罗切有限公司 3-苯基吡啶衍生物及其作为nk-1受体拮抗剂的应用
CN1131212C (zh) 1999-02-24 2003-12-17 弗·哈夫曼-拉罗切有限公司 苯基－和吡啶基衍生物
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
WO2000053772A1 (fr) 1999-03-06 2000-09-14 Roche Diagnostics Gmbh Adn-polymerase obtenue a partir de $i(pyrobaculum islandicum)
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
TW550258B (en) 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ES2208205T3 (es) 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
CA2415890C (fr) 2000-07-14 2009-04-07 F. Hoffmann-La Roche Ag N-oxydes en tant que promedicaments de derives de 4-phenyl-pyridine, antagonistes du recepteur nk1
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
DE60123661T2 (de) 2000-12-14 2007-08-16 F. Hoffmann-La Roche Ag Selbstemulgierende lipidmatrix (selm)
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
MXPA03009720A (es) 2001-04-23 2004-01-29 Hoffmann La Roche USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
DE60227657D1 (de) 2001-05-14 2008-08-28 Hoffmann La Roche 1-OXA-3,9-DIAZASPIROc5.5ÜUNDECAN-2-ONDERIVATE UND ZEPTORS
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
EP1501804B1 (fr) 2002-04-26 2009-08-26 F. Hoffmann-La Roche Ag Derives d'isoquinoleine inhibiteurs de mao-b
ES2324214T3 (es) 2002-05-29 2009-08-03 F. Hoffmann-La Roche Ag Derivados de n-acilaminobenceno como inhibidores de la monoamina oxidasa b selectiva.
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
MY134480A (en) 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
MXPA05006124A (es) 2002-12-13 2005-08-16 Hoffmann La Roche Derivados de 3-quinazolin-4-ona.
CN100562320C (zh) 2003-01-31 2009-11-25 弗·哈夫曼-拉罗切有限公司 2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics

Also Published As

Publication number Publication date
NZ560232A (en) 2010-11-26
TW200640502A (en) 2006-12-01
WO2006089674A3 (fr) 2007-02-08
AU2006218193A1 (en) 2006-08-31
KR20070094666A (ko) 2007-09-20
MX2007009571A (es) 2007-09-21
NO20074092L (no) 2007-09-04
US20090304795A1 (en) 2009-12-10
IL185011A0 (en) 2007-12-03
WO2006089674A2 (fr) 2006-08-31
JP2008531509A (ja) 2008-08-14
BRPI0606187A2 (pt) 2009-06-09
CA2598762A1 (fr) 2006-08-31
CN101128189A (zh) 2008-02-20
EP2281556A1 (fr) 2011-02-09
UA90708C2 (ru) 2010-05-25
US20060193910A1 (en) 2006-08-31
CR9292A (es) 2010-04-21
AR055561A1 (es) 2007-08-22
RU2007129642A (ru) 2009-03-27
ZA200706495B (en) 2008-10-29
EP1855655A2 (fr) 2007-11-21

Similar Documents

Publication Publication Date Title
MA29268B1 (fr) Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse
CA2366027C (fr) Comprime orodispersible presentant une faible friabilite et son procede de preparation
KR101665001B1 (ko) ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
KR101640164B1 (ko) ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
FR2460667A1 (fr) Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide
CA2534997A1 (fr) Methodes d'administration de l'aripiprazole
WO2008037557A3 (fr) Médicaments anti-inflammatoires non stéroïdiens solubilisés
EP1985288B1 (fr) Préparation solide orale et son procédé de fabrication
JP6103111B1 (ja) 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
TWI492747B (zh) 壓縮製劑
EP0290299B1 (fr) Forme galénique à base d'extrait sec de plantes
EP1646373B1 (fr) Composition pharmaceutique orodispersible d'un compose antithrombotique
FR2467596A1 (fr) Compositions pharmaceutiques de tiaramide ou de son sel et d'un agent reglant la dissolution, a longue duree d'action
WO2007086911A3 (fr) Formulations nanoparticulaires stables
RU2005131494A (ru) Твердая лекарственная форма, содержащая десмопрессин
CN113365611A (zh) 制备包含奈福泮和对乙酰氨基酚的药物组合物的方法和由该方法获得的药物组合物
EP3139905B1 (fr) Co-granules de gomme de xanthane et de gomme d'acacia
CA3106495C (fr) Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique
RU2010129544A (ru) Фармацевтическая композиция
FR2785191A1 (fr) Utilisation de gommes xanthanes pour la preparation de compositions pharmaceutiques
TH81384A (th) ยาเม็ดที่มีการปรับปรุงความสามารถในการกระจายของสารตัวยา
FR2584604A1 (fr) Composition therapeutique constituant une nouvelle forme galenique orale pour ameliorer la cinetique de la biodisponibilite
Narode et al. FORMULATION AND INVIVO EVALUATION OF METHOTREXATE HOT MELT EXTRUDES USING KOLLIDON VA 64 & PEG 1500
WO2008089773A1 (fr) Formulation d'une matrice a desintegration rapide
TH59782A3 (th) สารผสมของกาแลนแทมีนชนิดปลดปล่อยที่มีการควบคุม